Check the time stamp on this data. Updated AI-Generated Signals for Denali Therapeutics Inc. (DNLI) available here: DNLI.

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

A month has gone by since the last earnings report for Denali Therapeutics Inc. (DNLI). Shares have lost about 21.2% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

Pitcairn Co. purchased a new position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 3rd quarter, ...

DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.

Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...

DNLI opened at $23.70 on Thursday. The stock’s 50-day moving average price is $26.97 and its 200 day moving average price is $24.58. Denali Therapeutics Inc. has a 12-month low of $14.56 and a ...

Denali Therapeutics Inc. DNLI initiated dosing in a global mid-stage study, BEACON, on BIIB122 (DNL151). BIIB122, an investigational drug leucine-rich repeat kinase 2 (LRRK2) inhibitor ...